In patients with moderate peripheral artery disease, use of GLP-1 RAs increases the likelihood of more favorable cardiovascular and major limb outcomes.

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

Canada: A recent observational cohort study from Canada revealed that older diabetic patients taking GLP-1 receptor ...

The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...

New research shows GLP-1 drugs may be linked to a twofold increase in the risk of wet AMD among people with diabetes.

Semaglutide use may be increasing worldwide rates of ischemic optic neuropathy and retinal adverse events, a study suggests.

Navitus, the nation’s first transparent, pass-through pharmacy benefit manager (PBM), released its ninth annual Drug Trend ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

GLP-1 RAs may significantly increase the risk of neovascular age-related macular degeneration in older adults with diabetes.

Canadian researchers find that taking semaglutide increases the chances of developing neovascular age-related macular ...